Next Article in Journal
Chemical Profiling and Bioactivity Assessment of Helichrysum italicum (Roth) G. Don. Essential Oil: Exploring Pure Compounds and Synergistic Combinations
Previous Article in Journal
Metabolomics and Proteomics Responses of Largemouth Bass (Micropterus salmoides) Muscle under Organic Selenium Temporary Rearing
Previous Article in Special Issue
Non-Toxic Dimeric Peptides Derived from the Bothropstoxin-I Are Potent SARS-CoV-2 and Papain-like Protease Inhibitors
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 14
10.3390/molecules28145300
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dietary Supplementation of Aspirin Promotes Drosophila Defense against Viral Infection

by
Fanrui Kong
1,†,
Abdul Qadeer
1,†,
Yali Xie
1,†,
Yiheng Jin
1,
Qingyang Li
1,
Yihua Xiao
1,
Kan She
1,
Xianrui Zheng
2,
Jiashu Li
3,
Shanming Ji
1,3,* and
Yangyang Zhu
1,*
1
Center for Developmental Biology, School of Life Sciences, Anhui Agricultural University, Hefei 230036, Anhui, China
2
Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou 363000, Fujian, China
3
Université de Strasbourg, 67000 Strasbourg, France
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2023, 28(14), 5300; https://doi.org/10.3390/molecules28145300
Submission received: 3 May 2023 / Revised: 28 June 2023 / Accepted: 7 July 2023 / Published: 9 July 2023
(This article belongs to the Special Issue Recent Advances in Antiviral Agents)
Browse Figures
Review Reports Versions Notes

Abstract

:
Aspirin, also known as acetylsalicylic acid, is widely consumed as a pain reliever and an anti-inflammatory as well as anti-platelet agent. Recently, our studies using the animal model of Drosophila demonstrated that the dietary supplementation of aspirin renovates age-onset intestinal dysfunction and delays organismal aging. Nevertheless, it remains probable that aspirin plays functional roles in other biological activities, for instance antiviral defense reactions. Intriguingly, we observed that the replications of several types of viruses were drastically antagonized in Drosophila macrophage-like S2 cells with the addition of aspirin. Further in vivo experimental approaches illustrate that adult flies consuming aspirin harbor higher resistances to viral infections with respect to flies without aspirin treatment. Mechanistically, aspirin positively contributes to the Drosophila antiviral defense largely through mediating the STING (stimulator of interferon genes) but not the IMD (immune deficiency) signaling pathway. Collectively, our studies uncover a novel biological function of aspirin in modulating Drosophila antiviral immunity and provide theoretical bases for exploring new antiviral treatments in clinical trials.

1. Introduction

Viruses are a type of microorganism that may have a wide range of negative effects on the human body including damages to tissues/organs, immune system dysfunctions, respiratory illnesses, neurological symptoms, and increased risks of cancers. In order to prevent or treat viral infections, a large body of efforts have been dedicated to the field of “exploring antiviral drugs”, which was obviously one of the hottest scientific topics during the global pandemic of COVID-19 (caused by the SARS-CoV-2 virus). In general, antiviral drugs function by targeting specific parts of viruses, thereby preventing them from reproducing and spreading throughout the body. When taken as directed, these drugs can help to reduce the severity and duration of viral illnesses and prevent complications (for details, please see reviews including [1,2,3,4,5,6,7]). To date, there has been a significant breakthrough in the development of antiviral drugs, as many of them, including nucleoside inhibitors, protease inhibitors, neuraminidase inhibitors, entry inhibitors, RNA polymerase inhibitors, and integrase inhibitors, have been successively adopted in clinical trials. Nevertheless, antiviral drugs are not always a promise due to the facts that (1) viruses are notoriously difficult to combat as they are able to mutate quickly and develop resistance to drugs; (2) novel viruses, for instance SARS-CoV-2, regularly emerge and cause outbreaks, but existing antiviral drugs are ineffective against them. Therefore, exploring new antiviral drugs/compounds is crucial for responding to the ongoing threats posed by viral diseases.
The fruit fly (Drosophila melanogaster) has long been used as an animal model for studying a wide range of biological processes and diseases, including viral infections. In recent decades, there have been growing interests in utilizing Drosophila for identifying and testing potential antiviral drugs [8,9]. One advantage of using Drosophila as a model organism is that Drosophila has a relatively simple and well-characterized immune system, which makes it quite easy to study the interactions between viruses and host cells. In addition, Drosophila is a type of cost-effective and easy-to-maintain insect that can be used in large-scale screening assays in order to identify potential antiviral compounds [10,11]. For instance, a study by Adamson and colleagues established a Drosophila model of influenza virus infection by stably expressing the M2 gene in specific tissues/organs [12]. They confirmed the antiviral efficiency of amantadine in restricting influenza titers, supporting the probable use of this system for high-throughput antiviral drug screening [12]. Another approach of infecting flies with HSV (herpes simplex virus) identified potential host factors that could be targeted by antiviral drugs [13]. Moreover, Lee and colleagues lately succeeded in expressing the Orf6 (open reading frame 6) gene of SARS-CoV-2 in fly tissues, which displayed corresponding disease phenotypes [14], making it even more promising to explore functional materials against COVID-19. Overall, the use of Drosophila as a model organism for exploring antiviral drugs is an active area of scientific research, and has the potential to identify new compounds and targets for treating viral infections.
Aspirin (acetylsalicylic acid), a type of well-known NSAID (nonsteroidal anti-inflammatory drug), is commonly consumed by patients in order to relieve pain, reduce inflammation, and lower fever (reviewed in [15,16]). Although it is not typically used as an antiviral drug, recent in vitro studies have shown that it may inhibit the replication of several types of viruses, including HCV (hepatitis C virus), influenza virus, HSV (herpes simplex virus), and HIV (human immunodeficiency virus) [17,18,19]. However, it remains largely unknown whether or not aspirin executes antiviral activity in vivo. We lately reported the beneficial effect of aspirin on preventing age-onset gut epithelial dysfunction and delaying aging in Drosophila [20]. Encouraged by this, our next objective is to explore the potential antiviral role of aspirin by utilizing a fruit fly animal model.
In the present study, we provide in vivo evidence displaying that the dietary consumption of aspirin positively contributes to the fly antiviral defense against various types of viruses. Of interest is that aspirin likely mediates the STING (stimulator of interferon genes) but not the IMD (immune deficiency) signaling pathway to exert its essential role in the host defense against viral infections. Collectively, our studies shed light on the physiological function of aspirin in antiviral immunity and provide bases for the clinical usage of aspirin as an antiviral drug/treatment.

2. Results

2.1. Additional Aspirin Leads to Decreased Viral Titers in Drosophila S2 Cells

We first carried out experiments on Drosophila macrophage-like S2 cells to confirm the antiviral function of aspirin. Cultured S2 cells were pretreated with aspirin at various concentrations (0.1 and 0.5 mM, respectively), followed by infection from DCV (Drosophila C virus), which is one of the widely utilized viruses to infect S2 cells. As illustrated in Figure 1A, the viral titer of DCV was drastically decreased in S2 cells with additional aspirin (0.1 mM) compared to that in the control group. A more significant trend was observed when S2 cells were treated with a higher dose of aspirin (0.5 mM) (Figure 1A). These results suggested that aspirin prevents viral replication in a concentration-dependent manner. We next examined the impact of aspirin on the loads of other types of viruses. A strong decrease in CrPV (cricket paralysis virus) RNA was noticed in S2 cells with the treatment of aspirin (Figure 1B). A similar effect was also detected when S2 cells were infected with another RNA virus, VSV (vesicular stomatitis virus) (Figure 1C). However, additional aspirin hardly affected the titers of either SINV (sindbis virus) (Figure 1D) or DNA virus IIV6 (invertebrate iridescent virus 6) (Figure 1E). Taken together, our data support the notion that aspirin antagonizes viral replication in cultured Drosophila S2 cells largely depending on the specific type of virus.

2.2. Viral Proliferation Is Limited in Adult Flies with Dietary Supplementation of Aspirin

Encouraged by this, we then sought to illustrate whether or not aspirin executes antiviral activity in vivo. To determine this, we first raised the wild-type (w1118 or Canton-S) flies with a medium supplemented with different concentrations of aspirin (0, 0.5, and 1 mg/L, respectively) and the dietary addition of aspirin hardly affected the food consumption of tested flies [20]. We then infected these flies with DCV and detected the viral titer on the following days (day 0, 1, and 2). As demonstrated in Figure 2A and Figure S1A, on day 1 after infection, the DCV RNA levels were markedly reduced in the flies consuming 0.5 mg/L of aspirin with respect to those in the control group. A greater reduction was detected when flies were supplemented with a higher dose of aspirin (1 mg/L) (Figure 2A and Figure S1A). Consistently, similar results were obtained when flies were collected for monitoring the viral titers on day 2 after infection (Figure 2A and Figure S1A), implying that aspirin harbors antiviral function in adult flies. To further confirm these observations, we infected w1118 males with other types of viruses, including CrPV and VSV. Intriguingly, the replications of both viruses were limited in the host flies by aspirin in a dosage-dependent manner (Figure 2B,C).

2.3. Dietary Supplementation of Aspirin Enhances Fly Survival after Viral Infection

Since the viral load was decreased in flies consuming aspirin, one would expect the stronger resistance of these flies against viral infection. Indeed, when we conducted survival rate assays after viral infections, we observed an increased viability of flies with the dietary addition of aspirin, compared to that of the controls (Figure 2D,G).
In summary, our data indicate that aspirin behaves as an antiviral compound in the fly defense against viral infection.

2.4. Aspirin Modulates Fly Survival and Viral Titers after Infection in an IMD-Independent Manner

We then aimed to illustrate how aspirin benefits the antiviral defense of Drosophila. Based upon our recent finding that aspirin delays fly aging via targeting Imd [20], which is a key adaptor protein in the IMD (immune deficiency) innate immune pathway [21], and the fact that the IMD signal plays an essential role in Drosophila antiviral immunity [22], we would like to hypothesize that aspirin executes an antiviral function via mediating Imd. In this regard, we examined the antiviral role of aspirin in the imd LOF (loss of function) mutant flies. Unexpectedly, the dietary supplementation of aspirin still restricted the replication of injected DCV (Figure 3A) and promoted the survival of the imd LOF mutants (Figure 3B). These results implied that imd is largely not responsible for aspirin positively contributing to the fly antiviral defense.

2.5. Aspirin Relies on Sting and Relish to Regulate Fly Survival and Viral Replication after Infection

Pioneering studies have delineated that in addition to the IMD signaling cascade, the Toll [23], JAK-STAT (Janus kinase-signal transducer and activator of transcription) [24], RNAi (RNA interference) [25], autophagy [26], and STING (stimulator of interferon genes) [27] pathways are also involved in governing the antiviral immune defense system of Drosophila. We then sought to identify whether or not aspirin mediates one (or some) of them to unleash its antiviral activity. As shown in Figure 3C–J, the dif (dorsal-related immunity factor), hop (hopscotch), ago2 (argonaute 2), or atg7 (autophagy-related 7) LOF mutant flies supplemented with aspirin displayed decreased mortalities. The DCV loads in these flies were reduced after viral injection (Figure 3C,J). However, when we dietarily supplemented the sting LOF mutants with aspirin, we observed that aspirin almost failed to affect fly survival and the viral titer upon DCV infection (Figure 4A,B). Moreover, we obtained similar results when we performed these assays utilizing the rel (relish) LOF mutant flies (Figure 4C,D). Collectively, our data indicated that aspirin benefits the fly antiviral defense largely in a STING-NF-kB (nuclear factor kappa B) signal-dependent manner.

2.6. Additional Aspirin Increases the Expressions of STING-Induced Genes

To obtain more evidence, we examined whether or not the expressions of STING downstream antiviral effectors are modulated by aspirin. When we infected the wild-type flies with DCV under normal rearing conditions, we detected enormous inductions of nazo and srg1 (STING-regulated gene 1) (Figure 4E,F), which were consistent with previous findings [27,28]. Of interest is that the dietary supplementation of aspirin drastically increased the transcript levels of both nazo and srg1, but this was not the case in the sting LOF mutants (Figure 4E,F). These results indicate that aspirin positively participates in Drosophila antiviral defense reactions through mediating the STING-NF-kB signaling cascade.

3. Discussion

In the present study, we conducted both in vitro and in vivo experimental approaches to identify the antiviral role of aspirin. We provided compelling evidence showing that the dietary supplementation of aspirin not only lowers the mortality rate of Drosophila upon the infection of specific viruses, but also prevents the viral loads in the host flies. Of note is that the loss of sting or rel reverses the advantageous assessment of aspirin in the fly antiviral defense, implying that aspirin benefits Drosophila antiviral immunity in a STING-NF-kB-dependent manner. Thus, our studies demonstrate the functional role of aspirin against viral infection in vivo.
Aspirin has long been well-known for its anti-inflammation and anti-platelet function, and widely utilized in medical treatments [15,16]. It was lately shown to harbor an antiviral function [17,18,19,29], but these studies were mostly conducted in vitro systems. As a result, the prior objective of this research was to explore the potential involvement of aspirin in modulating the host antiviral defense reaction in vivo. To address this issue, we paid attention to the insect Drosophila, for which we have already succeeded in establishing the model of dietary consumption of aspirin and illustrating the anti-aging role of aspirin [20]. As expected, the dietary supplementation of aspirin significantly enhanced the expressions of antiviral effectors and the survival of flies upon viral infections. In this regard, our studies not only confirm the antiviral role of aspirin that was suggested in the previous literature [17,18,19,29], but also provide for the first-time in vivo evidence to support this notion. Of interest is that aspirin enables the antagonization of several types of viruses, making it possible to become a broad antiviral drug in clinical medication.
How does aspirin benefit the Drosophila antiviral defense? Our recent findings illustrated that aspirin down-regulates the K63 (63rd lysine)-linked ubiquitination of the Imd protein, thereby contributing to gut immune homeostasis and epithelial function [20]. Therefore, we first explored whether or not aspirin is involved in the fly antiviral reaction via modulating Imd. Unexpectedly, dietary aspirin supplementation still enhanced the antiviral immunity in the imd LOF mutates. These observations encouraged us to further examine the antiviral role of aspirin in flies including dif, hop, ago2, atg7, or sting LOF mutants, where the known antiviral pathways (Toll, Jak-STAT, RNAi, autophagy, and STING-NF-κB, respectively) were blocked separately. Intriguingly, the STING-NF-κB signal turned out to be responsible for the antiviral activity of aspirin in adult flies. Nevertheless, knowledge regarding how aspirin modulates the STING-NF-κB signaling pathway is still lacking. Based upon our experience and knowledge with regard to the molecular mechanism by which aspirin can mediate protein ubiquitination, one mechanism we would like to propose is that the ubiquitination modification of a (some) key factor(s) in the STING-NF-κB signaling cascades is (are) regulated by aspirin.
Another question that needs to be addressed is that on which tissue/organ aspirin exerts its antiviral effect. Since we raised experimental flies with the dietary supplementation of aspirin, it is probable that aspirin functions in the digestive system to enhance fly metabolism, thereby contributing to the host antiviral response. In agreement with this, a previous transcriptomic analysis showed that aspirin can alter the expression of a series of genes involved in the metabolic pathway [30]. On the other hand, aspirin may circulate into fat body (the main immune tissue/organ during systemic infection), where it upregulates STING-NF-κB activity. It would thus be worthwhile in the future to explore (1) the potential regulatory relationship between aspirin and the Sting protein; (2) the antiviral function of aspirin in a tissue/organ-specific manner, for instance with the use of flies with the gut or fat body-specific RNAi of sting.

4. Significance and Limitations of this Study

Our studies uncover the functional involvement of aspirin in the fly defense against several types of viruses. Even though the genetic evidence implies an intersection between aspirin and the STING-NF-κB signaling pathway, the underlying molecular mechanism is still not fully addressed. Further experimental approaches at the levels of molecular biology and biochemistry are required to identify the substrate of aspirin and to illustrate how aspirin modulates the Drosophila STING-NF-κB signaling cascades.

5. Materials and Methods

5.1. Fly Strains and Husbandry

All flies in this study were raised under normal conditions (25 °C, 12 h/12 h light/dark cycle, and 60% humidity). The detailed information on flies in this study is as follows: (1) atg7d4 (#95244), hop3 (#8495), hop27 (#8493), and relE20 (#55714) were purchased from Bloomington Drosophila Stock Center; (2) the ago2414, dif1, IMD1, and STINGRxn strains were described previously [27,28,31,32].
To prepare the fly medium supplemented with aspirin, we first dissolved aspirin (#A2093, Sigma-Aldrich, St. Louis, USA) in sterile H2O (37 °C) at final concentrations of 0.5 and 1 g/L. Then, 1 mL of each aspirin solution was added into 1 L of the fly medium to prepare food with 0.5 or 1 mg/L of aspirin.

5.2. S2 Cell Manipulation

S2 cells were cultured in an insect medium (Hyclone, Amersham, UK) supplemented with 10% FBS (fetal bovine serum, Hyclone) and Penicillin/Streptomycin (Invitrogen, Carlsbad, USA). The MycoAlertTM kit (Lonza, Basel, Switzerland) was used for the mycoplasma detection and validation of the authenticity of S2 cells. For aspirin treatment in S2 cells, we first prepared a 5 and 10 mM aspirin solution (dissolved in sterile H2O). Then, 0.1 mL of each solution was added into S2 cells (0.9 mL) to reach the final concentration of aspirin, this being 0.5 or 1 mM, respectively. An equal volume of sterile H2O was added in the control group. Six hours after aspirin treatment, S2 cells were infected with DCV (MOI 1), CrPV (MOI 0.1), FHV (MOI 1), VSV (MOI 1), or IIV6 (MOI 1).

5.3. Viral Infection in Flies and Survival Rate Assays

Male flies (3 to 5 days old) were injected at the thorax with 4.6 nL of the viral particle solution (500 pfu per fly for DCV and VSV; 50 pfu per fly for CrPV) using a nanoliter injector (Nanoject III, Drummond, Broomall, USA). An equal volume of Tris-HCl solution (10 mM, pH = 7.5) was injected in the control group. Flies were then counted daily for survival. Flies that (<10%) died within 2 h were not considered in this assay.

5.4. RT-qPCR Assays

For cell samples, S2 cells were harvested and directly lysed in Trizol reagent (Invitrogen). For fly samples, animals were collected and homogenized in Trizol with glass beads. Total RNA was extracted using the standard chloroform–isopropanol method and the quality of RNA was examined via agarose gel electrophoresis. The reverse transcription kit (Transgen, Beijing, China) was used for cDNA synthesis and quantitative PCR assays were performed by using SYBR reagents (Invitrogen) [33]. Primers used in these experiments are outlined below. RpL32-s: GCCGCTTCAAGGGACAGTATCT; RpL32-as: AAACGCGGTTCTGCATGAT; DCV-s: TCATCGGTATGCACATTGCT; DCV-as: CGCATAACCATGCTCTTCTG; CrPV-s: GCTGAAACGTTCAACGCATA; CrPV-as: CCACTTGCTCCATTTGGTTT; FHV-s: TTTAGAGCACATGCGTCCAG; FHV-as: CGCTCACTTTCTTCGGGTTA; VSV-s: CATGATCCTGCTCTTCGTCA; VSV-as: TGCAAGCCCGGTATCTTATC; IIV6-s: TTGTTAGGAATTGGAACTGGAA; IIV6-as: GCCCTAGATGCTGCTTGTTC.

5.5. Statistical Analyses

All statistical analyses were performed using GraphPad Prism 8. The statistical significance in Figure 1A,E, Figure 2A,C, Figure 3A,C,E,G,I, Figure 4A,C,E and Figure S1A was determined using the ANOVA or Mann–Whitney tests. In Figure 2D,F, Figure 3B,D,F,H,J and Figure 4B,D,F, the log-rank test (Kaplan–Meier method) was used for statistical analysis. A p value of less than 0.05 was considered statistically significant. * indicates p < 0.05; ** indicates p < 0.01; *** indicates p < 0.001; ns indicates non-significance.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/molecules28145300/s1. Figure S1: Dietary supplementation of aspirin limits DCV load in Canton S flies.

Author Contributions

Conceptualization, S.J. and Y.Z.; methodology, F.K., A.Q. and Y.X. (Yali Xie); software, S.J. and Y.Z.; validation, F.K., A.Q., Y.X. (Yali Xie), Y.J. and Y.Z.; formal analysis, S.J. and Y.Z.; investigation, F.K., A.Q., Y.X. (Yali Xie), Y.J., Q.L., Y.X. (Yihua Xiao), K.S., X.Z. and J.L.; resources, F.K. and Y.Z.; data curation, F.K., A.Q., Y.X. (Yali Xie) and J.L.; writing—original draft preparation, S.J. and Y.Z.; writing—review and editing, S.J. and Y.Z.; visualization, S.J. and Y.Z.; supervision, S.J.; project administration, S.J.; funding acquisition, S.J. and Y.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by National Natural Science Foundation of China (grant number 32100702), Anhui Provincial Natural Science Foundation (grant number 2008085J14), and Research Funding for Outstanding Talents in Universities (grant number gxgwfx2020020).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data supporting the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgments

We are grateful for the critical reading and discussion by Qingshuang Cai (Institut de génétique biologie moléculaire et cellulaire). We thank Bloomington Drosophila Stock Center for fly resources.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compound aspirin are available from the authors.

References

  1. Martinez, J.P.; Sasse, F.; Bronstrup, M.; Diez, J.; Meyerhans, A. Antiviral drug discovery: Broad-spectrum drugs from nature. Nat. Prod. Rep. 2015, 32, 29–48. [Google Scholar] [CrossRef]
  2. Andreolla, A.P.; Borges, A.A.; Bordignon, J.; Dos Santos, C.N.D. Mayaro virus: The state-of-the-art for antiviral drug development. Viruses 2022, 14, 1787. [Google Scholar] [CrossRef]
  3. Ma-Lauer, Y.; Lei, J.; Hilgenfeld, R.; von Brunn, A. Virus-host interactomes--antiviral drug discovery. Curr. Opin. Virol. 2012, 2, 614–621. [Google Scholar] [CrossRef] [PubMed]
  4. Yoon, B.K.; Jeon, W.Y.; Sut, T.N.; Cho, N.J.; Jackman, J.A. Stopping membrane-enveloped viruses with nanotechnology strategies: Toward antiviral drug development and pandemic preparedness. ACS Nano 2021, 15, 125–148. [Google Scholar] [CrossRef]
  5. Park, S.; Tae, H.; Cho, N.J. Biophysical measurement strategies for antiviral drug development: Recent progress in virus-mimetic platforms down to the single particle level. Acc. Chem. Res. 2021, 54, 3204–3214. [Google Scholar] [CrossRef]
  6. de Chassey, B.; Meyniel-Schicklin, L.; Aublin-Gex, A.; Andre, P.; Lotteau, V. New horizons for antiviral drug discovery from virus-host protein interaction networks. Curr. Opin. Virol. 2012, 2, 606–613. [Google Scholar] [CrossRef]
  7. De Clercq, E. Antiviral drug discovery and development: Where chemistry meets with biomedicine. Antivir. Res. 2005, 67, 56–75. [Google Scholar] [CrossRef]
  8. Martins, N.; Imler, J.L.; Meignin, C. Discovery of novel targets for antivirals: Learning from flies. Curr. Opin. Virol. 2016, 20, 64–70. [Google Scholar] [CrossRef]
  9. Benoit, I.; Di Curzio, D.; Civetta, A.; Douville, R.N. Drosophila as a model for human viral neuroinfections. Cells 2022, 11, 2685. [Google Scholar] [CrossRef] [PubMed]
  10. Pandey, U.B.; Nichols, C.D. Human disease models in Drosophila melanogaster and the role of the fly in therapeutic drug discovery. Pharmacol. Rev. 2011, 63, 411–436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Ugur, B.; Chen, K.; Bellen, H.J. Drosophila tools and assays for the study of human diseases. Dis. Model Mech. 2016, 9, 235–244. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Adamson, A.L.; Chohan, K.; Swenson, J.; LaJeunesse, D. A Drosophila model for genetic analysis of influenza viral/host interactions. Genetics 2011, 189, 495–506. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Ullah, H.; Hou, W.; Dakshanamurthy, S.; Tang, Q. Host targeted antiviral (HTA): Functional inhibitor compounds of scaffold protein RACK1 inhibit herpes simplex virus proliferation. Oncotarget 2019, 10, 3209–3226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Lee, J.G.; Huang, W.; Lee, H.; van de Leemput, J.; Kane, M.A.; Han, Z. Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor. Cell Biosci. 2021, 11, 1–12. [Google Scholar] [CrossRef]
  15. Menter, D.G.; Bresalier, R.S. An aspirin a day: New pharmacological developments and cancer chemoprevention. Annu. Rev. Pharmacol. Toxicol. 2023, 63, 165–186. [Google Scholar] [CrossRef]
  16. Sehanobish, E.; Asad, M.; Barbi, M.; Porcelli, S.A.; Jerschow, E. Aspirin actions in treatment of NSAID-exacerbated respiratory disease. Front. Immunol. 2021, 12, 695815. [Google Scholar] [CrossRef]
  17. Glatthaar-Saalmuller, B.; Mair, K.H.; Saalmuller, A. Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study. Influenza Other Respir. Viruses 2017, 11, 85–92. [Google Scholar] [CrossRef]
  18. Pereira, C.F.; Paridaen, J.T.M.L.; Rutten, K.; Huigen, M.C.D.G.; van de Bovenkamp, M.; Middel, J.; Beerens, N.; Berkhout, B.; Schuurman, R.; Marnett, L.J.; et al. Aspirin-like molecules that inhibit human immunodeficiency virus 1 replication. Antivir. Res. 2003, 58, 253–263. [Google Scholar] [CrossRef]
  19. Rivas-Estilla, A.M.; Bryan-Marrugo, O.L.; Trujillo-Murillo, K.; Perez-Ibave, D.; Charles-Nino, C.; Pedroza-Roldan, C.; Rios-Ibarra, C.; Ramirez-Valles, E.; Ortiz-Lopez, R.; Islas-Carbajal, M.C.; et al. Cu/Zn superoxide dismutase (SOD1) induction is implicated in the antioxidative and antiviral activity of acetylsalicylic acid in HCV-expressing cells. Am. J Physiol. Gastrointest. Liver Physiol. 2012, 302, G1264–G1273. [Google Scholar] [CrossRef] [Green Version]
  20. Zhu, Y.; Cai, Q.; Zheng, X.; Liu, L.; Hua, Y.; Du, B.; Zhao, G.; Yu, J.; Zhuo, Z.; Xie, Z.; et al. Aspirin positively contributes to Drosophila intestinal homeostasis and delays aging through targeting Imd. Aging Dis. 2021, 12, 1821–1834. [Google Scholar] [CrossRef]
  21. Georgel, P.; Naitza, S.; Kappler, C.; Ferrandon, D.; Zachary, D.; Swimmer, C.; Kopczynski, C.; Duyk, G.; Reichhart, J.M.; Hoffmann, J.A. Drosophila immune deficiency (IMD) is a death domain protein that activates antibacterial defense and can promote apoptosis. Dev. Cell 2001, 1, 503–514. [Google Scholar] [CrossRef] [Green Version]
  22. Costa, A.; Jan, E.; Sarnow, P.; Schneider, D. The Imd pathway is involved in antiviral immune responses in Drosophila. PLoS ONE 2009, 4, e7436. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Zambon, R.A.; Nandakumar, M.; Vakharia, V.N.; Wu, L.P. The Toll pathway is important for an antiviral response in Drosophila. Proc. Natl. Acad. Sci. USA 2005, 102, 7257–7262. [Google Scholar] [CrossRef] [PubMed]
  24. Dostert, C.; Jouanguy, E.; Irving, P.; Troxler, L.; Galianna-Arnoux, D.; Hetru, C.; Hoffmann, J.A.; Imler, J.L. The Jak-STAT signaling pathway is required but not sufficient for the antiviral response of drosophila. Nat. Immunol. 2005, 6, 946–953. [Google Scholar] [CrossRef]
  25. Deddouche, S.; Matt, N.; Budd, A.; Mueller, S.; Kemp, C.; Galiana-Arnoux, D.; Dostert, C.; Antoniewski, C.; Hoffmann, J.A.; Imler, J.L. The DExD/H-box helicase Dicer-2 mediates the induction of antiviral activity in drosophila. Nat. Immunol. 2008, 9, 1425–1432. [Google Scholar] [CrossRef]
  26. Lamiable, O.; Arnold, J.; Faria, I.; Olmo, R.P.; Bergami, F.; Meignin, C.; Hoffmann, J.A.; Marques, J.T.; Imler, J.L. Analysis of the contribution of hemocytes and autophagy to Drosophila antiviral immunity. J. Virol. 2016, 90, 5415–5426. [Google Scholar] [CrossRef] [Green Version]
  27. Goto, A.; Okado, K.; Martins, N.; Cai, H.; Barbier, V.; Lamiable, O.; Troxler, L.; Santiago, E.; Kuhn, L.; Paik, D.; et al. The kinase IKKbeta regulates a STING- and NF-kappaB-dependent antiviral response pathway in Drosophila. Immunity 2018, 49, 225–234. [Google Scholar] [CrossRef] [Green Version]
  28. Cai, H.; Holleufer, A.; Simonsen, B.; Schneider, J.; Lemoine, A.; Gad, H.H.; Huang, J.; Huang, J.; Chen, D.; Peng, T.; et al. 2′3′-cGAMP triggers a STING- and NF-kappaB-dependent broad antiviral response in Drosophila. Sci. Signal. 2020, 13, 1–11. [Google Scholar] [CrossRef] [PubMed]
  29. Geiger, N.; Konig, E.M.; Oberwinkler, H.; Roll, V.; Diesendorf, V.; Fahr, S.; Obernolte, H.; Sewald, K.; Wronski, S.; Steinke, M.; et al. Acetylsalicylic acid and salicylic acid inhibit SARS-CoV-2 replication in precision-cut lung slices. Vaccines 2022, 10, 1619. [Google Scholar] [CrossRef]
  30. Song, C.; Zhu, C.; Wu, Q.; Qi, J.; Gao, Y.; Zhang, Z.; Gaur, U.; Yang, D.; Fan, X.; Yang, M. Metabolome analysis of effect of aspirin on Drosophila lifespan extension. Exp. Gerontol. 2017, 95, 54–62. [Google Scholar] [CrossRef]
  31. Cai, Q.; Ji, S.; Li, M.; Zheng, S.; Zhou, X.; Huo, H.; Deng, S.; Zhu, J.; Li, D.; Xie, Z. Theaflavin-regulated Imd condensates control Drosophila intestinal homeostasis and aging. iScience 2021, 24, 102150. [Google Scholar] [CrossRef] [PubMed]
  32. Kounatidis, I.; Ligoxygakis, P. Drosophila as a model system to unravel the layers of innate immunity to infection. Open Biol. 2012, 2, 1–14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Cai, Q.; Guo, H.; Fang, R.; Hua, Y.; Zhu, Y.; Zheng, X.; Yan, J.; Wang, J.; Hu, Y.; Zhang, C.; et al. A Toll-dependent Bre1/Rad6-cact feedback loop in controlling host innate immune response. Cell Rep. 2022, 41, 111795. [Google Scholar] [CrossRef] [PubMed]
Molecules 28 05300 g001 550
Figure 1. Aspirin prevents viral replication in Drosophila S2 cells. (A–E) Drosophila S2 cells were pretreated with aspirin (final concentration at 0, 0.1, and 0.5 mM, respectively) for 6 h. Cells were infected with viruses including DCV (A), CrPV (B), VSV (C), SINV (D), and IIV6 (E) as indicated. 24 h after viral infection, cells were lysed for viral titer examination. Each dot represents one independent replicate and data are shown as mean plus standard errors. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.
Figure 1. Aspirin prevents viral replication in Drosophila S2 cells. (A–E) Drosophila S2 cells were pretreated with aspirin (final concentration at 0, 0.1, and 0.5 mM, respectively) for 6 h. Cells were infected with viruses including DCV (A), CrPV (B), VSV (C), SINV (D), and IIV6 (E) as indicated. 24 h after viral infection, cells were lysed for viral titer examination. Each dot represents one independent replicate and data are shown as mean plus standard errors. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.
Molecules 28 05300 g001
Molecules 28 05300 g002 550
Figure 2. Dietary supplementation of aspirin promotes antiviral immunity in Drosophila. (A–C) Fresh male progenies of w1118 flies were collected and raised on the medium supplemented with aspirin (0, 0.5, and 1 mg/L, respectively). At the age of 3 to 5 days, flies were infected with viruses including DCV (A), CrPV (B), and VSV (C). At indicated time points (day 0, 1, and 2), flies were collected to monitor the viral loads. Each dot represents one independent replicate (5 flies) and data are shown as mean plus standard errors. (D–G) Male w1118 flies were raised and infected with Tris-HCl buffer (D) or viruses (E–G) similarly to the procedures followed in (A–C), followed by survival rate analyses. The numbers of flies are as follows. In (D), w1118 flies without aspirin: 106, 105, and 104; w1118 flies supplemented with 0.5 mg/L of aspirin: 104, 105, and 106; w1118 flies supplemented with 1 mg/L of aspirin: 105, 107, and 103. In (E), w1118 flies without aspirin: 102, 104, and 105; w1118 flies supplemented with 0.5 mg/L of aspirin: 104, 104, and 102; w1118 flies supplemented with 1 mg/L of aspirin: 105, 106, and 104. In (F), w1118 flies without aspirin: 105, 104, and 106; w1118 flies supplemented with 0.5 mg/L of aspirin: 102, 103, and 104; w1118 flies supplemented with 1 mg/L of aspirin: 104, 103, and 107. In (G), w1118 flies without aspirin: 104, 105, and 103; w1118 flies supplemented with 0.5 mg/L of aspirin: 103, 104, and 107; w1118 flies supplemented with 1 mg/L of aspirin: 106, 105, and 104. In (A–C) and (E–G), **, p < 0.01; ***, p < 0.001.
Figure 2. Dietary supplementation of aspirin promotes antiviral immunity in Drosophila. (A–C) Fresh male progenies of w1118 flies were collected and raised on the medium supplemented with aspirin (0, 0.5, and 1 mg/L, respectively). At the age of 3 to 5 days, flies were infected with viruses including DCV (A), CrPV (B), and VSV (C). At indicated time points (day 0, 1, and 2), flies were collected to monitor the viral loads. Each dot represents one independent replicate (5 flies) and data are shown as mean plus standard errors. (D–G) Male w1118 flies were raised and infected with Tris-HCl buffer (D) or viruses (E–G) similarly to the procedures followed in (A–C), followed by survival rate analyses. The numbers of flies are as follows. In (D), w1118 flies without aspirin: 106, 105, and 104; w1118 flies supplemented with 0.5 mg/L of aspirin: 104, 105, and 106; w1118 flies supplemented with 1 mg/L of aspirin: 105, 107, and 103. In (E), w1118 flies without aspirin: 102, 104, and 105; w1118 flies supplemented with 0.5 mg/L of aspirin: 104, 104, and 102; w1118 flies supplemented with 1 mg/L of aspirin: 105, 106, and 104. In (F), w1118 flies without aspirin: 105, 104, and 106; w1118 flies supplemented with 0.5 mg/L of aspirin: 102, 103, and 104; w1118 flies supplemented with 1 mg/L of aspirin: 104, 103, and 107. In (G), w1118 flies without aspirin: 104, 105, and 103; w1118 flies supplemented with 0.5 mg/L of aspirin: 103, 104, and 107; w1118 flies supplemented with 1 mg/L of aspirin: 106, 105, and 104. In (A–C) and (E–G), **, p < 0.01; ***, p < 0.001.
Molecules 28 05300 g002
Molecules 28 05300 g003 550
Figure 3. Aspirin enhances the antiviral defenses of several types of mutant flies. (A,B) The imd LOF mutants were raised in a medium supplemented with or without aspirin as indicated. Flies were infected with DCV and subjected to viral titer detection at various time points (A) or survival assays (B). (C–J) The dif (C,D), hop (E,F), ago2 (G,H), and atg7 (I,J) LOF mutants were subjected to similar experiments to those in (A,B). In (A,C,E,G,I), each dot represents one independent replicate (5 flies) and data are shown as mean plus standard errors. The numbers of flies for survival assays are as follows. In (B), imd−/− flies without aspirin: 102, 104, and 104; imd−/− flies supplemented with 0.5 mg/L of aspirin: 102, 105, and 106; imd−/− flies supplemented with 1 mg/L of aspirin: 104, 103, and 104. In (D), dif−/− flies without aspirin: 104, 103, and 105; dif−/− flies supplemented with 0.5 mg/L of aspirin: 102, 104, and 103; dif−/− flies supplemented with 1 mg/L of aspirin: 102, 106, and 104. In (F), hop−/− flies without aspirin: 105, 102, and 106; hop−/− flies supplemented with 0.5 mg/L of aspirin: 105, 105, and 103; hop−/− flies supplemented with 1 mg/L of aspirin: 103, 104, and 105. In (H), ago2−/− flies without aspirin: 101, 105, and 103; ago2−/− flies supplemented with 0.5 mg/L of aspirin: 104, 103, and 103; ago2−/− flies supplemented with 1 mg/L of aspirin: 103, 102, and 104. In (J), atg7−/− flies without aspirin: 105, 104, and 102; atg7−/− flies supplemented with 0.5 mg/L of aspirin: 103, 104, and 104; atg7−/− flies supplemented with 1 mg/L of aspirin: 102, 106, and 105. In (A–J), *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Figure 3. Aspirin enhances the antiviral defenses of several types of mutant flies. (A,B) The imd LOF mutants were raised in a medium supplemented with or without aspirin as indicated. Flies were infected with DCV and subjected to viral titer detection at various time points (A) or survival assays (B). (C–J) The dif (C,D), hop (E,F), ago2 (G,H), and atg7 (I,J) LOF mutants were subjected to similar experiments to those in (A,B). In (A,C,E,G,I), each dot represents one independent replicate (5 flies) and data are shown as mean plus standard errors. The numbers of flies for survival assays are as follows. In (B), imd−/− flies without aspirin: 102, 104, and 104; imd−/− flies supplemented with 0.5 mg/L of aspirin: 102, 105, and 106; imd−/− flies supplemented with 1 mg/L of aspirin: 104, 103, and 104. In (D), dif−/− flies without aspirin: 104, 103, and 105; dif−/− flies supplemented with 0.5 mg/L of aspirin: 102, 104, and 103; dif−/− flies supplemented with 1 mg/L of aspirin: 102, 106, and 104. In (F), hop−/− flies without aspirin: 105, 102, and 106; hop−/− flies supplemented with 0.5 mg/L of aspirin: 105, 105, and 103; hop−/− flies supplemented with 1 mg/L of aspirin: 103, 104, and 105. In (H), ago2−/− flies without aspirin: 101, 105, and 103; ago2−/− flies supplemented with 0.5 mg/L of aspirin: 104, 103, and 103; ago2−/− flies supplemented with 1 mg/L of aspirin: 103, 102, and 104. In (J), atg7−/− flies without aspirin: 105, 104, and 102; atg7−/− flies supplemented with 0.5 mg/L of aspirin: 103, 104, and 104; atg7−/− flies supplemented with 1 mg/L of aspirin: 102, 106, and 105. In (A–J), *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Molecules 28 05300 g003
Molecules 28 05300 g004 550
Figure 4. Loss of sting or rel prevents the antiviral activity of aspirin. (A,B) The sting LOF mutants were raised in medium supplemented with or without aspirin as indicated. Flies were infected with DCV and subjected to viral titer detection at various time points (A) or survival assays (B). (C,D) The rel LOF mutants were subjected to similar experiments to those in (A,B). (E,F) The sting LOF mutants and control flies were raised in a medium supplemented with or without aspirin. Flies were injected with Tris-HCl buffer or DCV as indicated, followed by RT-qPCR assays to monitor the expression levels of nazo (E) and srg1 (F). In (A,C,E,F), each dot represents one independent replicate (5 flies) and data are shown as mean plus standard errors. The numbers of flies for survival assays are as follows. In (B), sting−/− flies without aspirin: 101, 104, and 104; sting−/− flies supplemented with 0.5 mg/L of aspirin: 104, 105, and 102; sting−/− flies supplemented with 1 mg/L of aspirin: 103, 102, and 101. In (D), rel−/− flies without aspirin: 105, 103, and 102; rel−/− flies supplemented with 0.5 mg/L of aspirin: 102, 106, and 103; rel−/− flies supplemented with 1 mg/L of aspirin: 101, 102, and 104. In (A–F), **, p < 0.01; ***, p < 0.001; ns, not significant.
Figure 4. Loss of sting or rel prevents the antiviral activity of aspirin. (A,B) The sting LOF mutants were raised in medium supplemented with or without aspirin as indicated. Flies were infected with DCV and subjected to viral titer detection at various time points (A) or survival assays (B). (C,D) The rel LOF mutants were subjected to similar experiments to those in (A,B). (E,F) The sting LOF mutants and control flies were raised in a medium supplemented with or without aspirin. Flies were injected with Tris-HCl buffer or DCV as indicated, followed by RT-qPCR assays to monitor the expression levels of nazo (E) and srg1 (F). In (A,C,E,F), each dot represents one independent replicate (5 flies) and data are shown as mean plus standard errors. The numbers of flies for survival assays are as follows. In (B), sting−/− flies without aspirin: 101, 104, and 104; sting−/− flies supplemented with 0.5 mg/L of aspirin: 104, 105, and 102; sting−/− flies supplemented with 1 mg/L of aspirin: 103, 102, and 101. In (D), rel−/− flies without aspirin: 105, 103, and 102; rel−/− flies supplemented with 0.5 mg/L of aspirin: 102, 106, and 103; rel−/− flies supplemented with 1 mg/L of aspirin: 101, 102, and 104. In (A–F), **, p < 0.01; ***, p < 0.001; ns, not significant.
Molecules 28 05300 g004
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kong, F.; Qadeer, A.; Xie, Y.; Jin, Y.; Li, Q.; Xiao, Y.; She, K.; Zheng, X.; Li, J.; Ji, S.; et al. Dietary Supplementation of Aspirin Promotes Drosophila Defense against Viral Infection. Molecules 2023, 28, 5300. https://doi.org/10.3390/molecules28145300

AMA Style

Kong F, Qadeer A, Xie Y, Jin Y, Li Q, Xiao Y, She K, Zheng X, Li J, Ji S, et al. Dietary Supplementation of Aspirin Promotes Drosophila Defense against Viral Infection. Molecules. 2023; 28(14):5300. https://doi.org/10.3390/molecules28145300

Chicago/Turabian Style

Kong, Fanrui, Abdul Qadeer, Yali Xie, Yiheng Jin, Qingyang Li, Yihua Xiao, Kan She, Xianrui Zheng, Jiashu Li, Shanming Ji, and et al. 2023. "Dietary Supplementation of Aspirin Promotes Drosophila Defense against Viral Infection" Molecules 28, no. 14: 5300. https://doi.org/10.3390/molecules28145300

APA Style

Kong, F., Qadeer, A., Xie, Y., Jin, Y., Li, Q., Xiao, Y., She, K., Zheng, X., Li, J., Ji, S., & Zhu, Y. (2023). Dietary Supplementation of Aspirin Promotes Drosophila Defense against Viral Infection. Molecules, 28(14), 5300. https://doi.org/10.3390/molecules28145300

Article Metrics

Back to TopTop